Previous 10 |
home / stock / khtrf / khtrf news
Knight Therapeutics ( OTC:KHTRF ): Q3 GAAP EPS of -C$0.021. More news on: Knight Therapeutics Inc., Earnings news and commentary, Read more ...
Knight Therapeutics ( OTC:KHTRF ) has agreed to acquire Montevideo, Uruguay-based Biotoscana Investments S.A. ("Grupo Biotoscana") for BRL 1,164M (C$369M). More news on: Knight Therapeutics Inc., Healthcare stocks news, Merger & acquisition news, Read more ...
Knight Therapeutics Inc. (KHTRF) Q2 2019 Earnings Conference Call August 08, 2019, 08:30 AM ET Company Participants Jonathan Ross Goodman - CEO Samira Sakhia - President and CFO Amal Khouri - VP, Business Development Arvind Utchanah - VP, Finance Conference Call Participants...
Knight Therapeutics ( OTC:KHTRF ): Q2 GAAP EPS of C$0.13. More news on: Knight Therapeutics Inc., Earnings news and commentary, Read more ...
Knight Therapeutics Inc. (KHTRF) Q1 2019 Earnings Conference Call May 09, 2019 08:30 AM ET Company Participants Jonathan Ross Goodman - CEO Samira Sakhia - CFO Amal Khouri - VP, Business Development Presentation Operator Good morning, ladies and gentlemen. My name is Ju...
Knight Therapeutics ( OTC:KHTRF ): Q1 GAAP EPS of C$0.04. More news on: Knight Therapeutics Inc., Earnings news and commentary, Read more ...
Knight Therapeutics Inc. (KHTRF) Q4 2018 Earnings Conference Call March 14, 2019 08:30 AM ET Company Participants Jonathan Ross Goodman - Chief Executive Officer Samira Sakhia – President & Chief Financial Officer Amal Khouri - Vice President of Business Development ...
Knight Therapeutics ( OTC:KHTRF ): Q4 GAAP EPS of C$0.00. More news on: Knight Therapeutics Inc., Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Knight Therapeutics Inc Company Name:
KHTRF Stock Symbol:
OTCMKTS Market:
Knight Therapeutics Inc Website:
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive supply and distribution agreement with Ironshore Pharmaceuticals & Development, Inc., a wh...
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2024. All currency amounts are in ...
MONTREAL, May 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2024 R...